These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10708054)

  • 21. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children.
    Miller TL; Mawn BE; Orav EJ; Wilk D; Weinberg GA; Nicchitta J; Furuta L; Cutroni R; McIntosh K; Burchett SK; Gorbach SL
    Pediatrics; 2001 May; 107(5):E77. PubMed ID: 11331727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The metabolic effects of lopinavir/ritonavir in HIV-negative men.
    Lee GA; Seneviratne T; Noor MA; Lo JC; Schwarz JM; Aweeka FT; Mulligan K; Schambelan M; Grunfeld C
    AIDS; 2004 Mar; 18(4):641-9. PubMed ID: 15090769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy.
    Chantry CJ; Hughes MD; Alvero C; Cervia JS; Meyer WA; Hodge J; Borum P; Moye J;
    Pediatrics; 2008 Jul; 122(1):e129-38. PubMed ID: 18519448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy.
    Estrada V; Serrano-Ríos M; Martínez Larrad MT; Villar NG; González López A; Téllez MJ; Fernández C
    J Acquir Immune Defic Syndr; 2002 Jan; 29(1):32-40. PubMed ID: 11782587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.
    Aldrovandi GM; Lindsey JC; Jacobson DL; Zadzilka A; Sheeran E; Moye J; Borum P; Meyer WA; Hardin DS; Mulligan K;
    AIDS; 2009 Mar; 23(6):661-72. PubMed ID: 19279441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.
    Shlay JC; Visnegarwala F; Bartsch G; Wang J; Peng G; El-Sadr WM; Gibert C; Kotler D; Grunfeld C; Raghavan S;
    J Acquir Immune Defic Syndr; 2005 Feb; 38(2):147-55. PubMed ID: 15671799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
    Ruiz L; Negredo E; Domingo P; Paredes R; Francia E; Balagué M; Gel S; Bonjoch A; Fumaz CR; Johnston S; Romeu J; Lange J; Clotet B;
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):229-36. PubMed ID: 11464141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients.
    Pernerstorfer-Schoen H; Schindler K; Parschalk B; Schindl A; Thoeny-Lampert S; Wunderer K; Elmadfa I; Tschachler E; Jilma B
    AIDS; 1999 Dec; 13(17):2389-96. PubMed ID: 10597780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.
    Kosmiski LA; Kuritzkes DR; Lichtenstein KA; Glueck DH; Gourley PJ; Stamm ER; Scherzinger AL; Eckel RH
    AIDS; 2001 Oct; 15(15):1993-2000. PubMed ID: 11600828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women.
    Hadigan C; Miller K; Corcoran C; Anderson E; Basgoz N; Grinspoon S
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1932-7. PubMed ID: 10372689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART).
    Dong KL; Bausserman LL; Flynn MM; Dickinson BP; Flanigan TP; Mileno MD; Tashima KT; Carpenter CC
    J Acquir Immune Defic Syndr; 1999 Jun; 21(2):107-13. PubMed ID: 10360801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole body leucine flux in HIV-infected patients treated with or without protease inhibitors.
    Prod'homme M; Rochon C; Balage M; Laurichesse H; Tauveron I; Champredon C; Thieblot P; Beytout J; Grizard J
    Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E685-93. PubMed ID: 16249256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperlipidemia in HIV-positive patients receiving antiretrovirals.
    Segarra-Newnham M
    Ann Pharmacother; 2002 Apr; 36(4):592-5. PubMed ID: 11918504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults.
    Blázquez D; Ramos-Amador JT; Saínz T; Mellado MJ; García-Ascaso M; De José MI; Rojo P; Navarro ML; Muñoz-Fernández MÁ; Saavedra J; Roa MA; Jiménez S; Beceiro J; Prieto L; Hortelano MG; González-Tomé MI
    BMC Infect Dis; 2015 Mar; 15():119. PubMed ID: 25880777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression.
    Hung TC; Chen GJ; Cheng SH; Chen JH; Wei JL; Cheng CY; Hung CC
    J Microbiol Immunol Infect; 2019 Dec; 52(6):865-871. PubMed ID: 31422059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy.
    Moyle GJ; Baldwin C; Langroudi B; Mandalia S; Gazzard BG
    J Acquir Immune Defic Syndr; 2003 May; 33(1):22-8. PubMed ID: 12792351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
    Petit JM; Duong M; Masson D; Buisson M; Duvillard L; Bour JB; Brindisi MC; Galland F; Guiguet M; Gambert P; Portier H; Vergès B
    Eur J Clin Invest; 2004 Aug; 34(8):569-75. PubMed ID: 15305892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
    Fisac C; Fumero E; Crespo M; Roson B; Ferrer E; Virgili N; Ribera E; Gatell JM; Podzamczer D
    AIDS; 2005 Jun; 19(9):917-25. PubMed ID: 15905672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.
    Fisac C; Virgili N; Ferrer E; Barbera MJ; Fumero E; Vilarasau C; Podzamczer D
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5186-92. PubMed ID: 14602748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children.
    Bitnun A; Sochett E; Babyn P; Holowka S; Stephens D; Read S; King SM
    AIDS; 2003 Jun; 17(9):1319-27. PubMed ID: 12799553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.